Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting.

Oncoimmunology - 1 Jan 2022

Kato Shumei, Li Bing, Adashek Jacob J, Cha Seong Won, Bianchi-Frias Daniella, Qian Dajun, Kim Lisa, So Tiffany W, Mitchell Marcus, Kamei Naoki, Hoiness Robert, Hoo Jayne, Gray Phillip N, Iyama Teruaki, Kashiwagi Masahide, Lu Hsiao-Mei, Kurzrock Razelle

Abstract excerpt

Major immunotherapy challenges include a limited number of predictive biomarkers and the unusual imaging features post-therapy, such as pseudo-progression, which denote immune infiltrate-mediated tumor enlargement. Such phenomena confound clinical decision-making, since the cancer may eventually regress, and the patient should stay on treatment. We prospectively evaluated serial, blood-derived cell-free DNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gene Frequency
Share to Immune Checkpoint Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liquid Biopsy

Share to Mutation

Share to Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 35371621
DOI: 10.1080/2162402X.2022.2052410
PMCID: PMC8966985

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting.PMID 35371621Read ↗

Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy.Semantic proximity Read ↗

In-depth assessment of BRAF, NRAS, KRAS, EGFR, and PIK3CA mutations on cell-free DNA in the blood of melanoma patients receiving immune checkpoint inhibitionSemantic proximity Read ↗

Validity and utility of blood tumor mutational burden is dependent on circulating tumor DNA shedSemantic proximity Read ↗

Intra-patient stability of tumor mutational burden from tissue biopsies at different time points in advanced cancers.Semantic proximity Read ↗

Integrating clinico-pathological features and longitudinal liquid biopsy results to predict clinical benefit from immune checkpoint Inhibitors in advanced Non-Small Cell Lung Cancer patientsSemantic proximity Read ↗

Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Non‐Small Cell Lung CancerSemantic proximity Read ↗

Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivitySemantic proximity Read ↗

Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.Semantic proximity Read ↗

Lesion-Directed Therapies and Monitoring Tumor Evolution Using Liquid Biopsies.Semantic proximity Read ↗

Viewpoint: The Current Advances and Future Optimization of Blood-based Tumor Mutation Burden as a Biomarker for Cancer ImmunotherapySemantic proximity Read ↗

Molecular counting enables accurate and precise quantification of methylated ctDNA for tumor-naive cancer therapy response monitoringSemantic proximity Read ↗

Circulating Tumor DNA: A Promising Biomarker for Predicting Recurrence in Patients with BRAF-Negative Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.